Keywords: CSF; cerebrospinal fluid; GAD; glutamic acid decarboxylase; ICI; immune checkpoint inhibitor; irAE; immune-related adverse effect; MRI; magnetic resonance imaging; PCD; paraneoplastic cerebellar degeneration; PD-1; programmed death-1;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Head and neck cancer; PD-1; Immune checkpoint blockade;
Keywords: PD-L1; PD-1; Immunohistochemistry; Sequencing; Mutational load; Primary lung; Metastasis;
Keywords: Biomarker; Brain tumor; Diagnosis; Meningioma; Molecular characterization; Prognosis; Recurrence; AKT1; v-Akt murine thymoma viral oncogene homolog 1; BAP1; BRCA1-associated protein 1; CDKN2A and B; Cyclin-dependent kinase inhibitor 2A and 2B; FAK; Focal
Keywords: Immune effect; PD-1; Radioisotope; Survival; Xofigo;
Keywords: Immune checkpoint inhibitors; Biomarkers; Clinical studies; Immunotherapy; Hematologic malignancies; CTLA-4; PD-1;
Keywords: Localized; Muscle-invasive; Non-muscle-invasive; Bladder cancer; Checkpoint inhibitor; PD-1; PD-L1; CTLA-4; Treatment; Therapy;
Keywords: Colorectal cancer; Mismatch repair deficiency; PD-1; PD-L1; Tumor immune microenvironment;
Keywords: Immune-checkpoint inhibitors; Metastatic urothelial carcinoma; Meta-analysis; Systematic review; PD-1; PD-L1;
Keywords: Thyroiditis; PD-1; CTLA-4; Ipilimumab; Nivolumab; Cytology;
Keywords: Nasopharyngeal carcinoma; Epstein-Barr virus; Immunotherapy; Cellular-based therapy; Vaccination; Head and neck cancer; DC; dendritic cell; NK; natural killer cell; CTL; cytotoxic T lymphocyte/cell; NPC; nasopharyngeal carcinoma; HLA; human leukocyte anti
Keywords: ARG-1; arginase 1; CCL-; CC motif chemokine ligand-; CXCL-; CX-C motif chemokine ligand-; CAF; cancer associated fibroblast; CO; carbon monoxide; CVB3; coxsackievirus B3; COX-2; cyclooxygenase-2; DC; dendritic cell; EAU; experimental autoimmune uveitis; E
Keywords: PD-1; programed cell death-1; PD-L1; programmed cell death ligand 1; NSCLC; non-small-cell lung cancer; OS; overall survival; PFS; progression-free survival; ORR; objective response rate; irAEs; immune-related adverse events; RECIST; response evaluation c
Keywords: Cervical cancer; Immune check-point; Immunotherapy; CTLA-4; PD-1; Ipilimumab; Pembrolizumab; Nivolumab;
Keywords: Anticoagulants; Cytokine; Luminex; Validation; Serum; Plasma; IL; interleukin; CC; CC-chemokine (beta chemokine); CXC; CXC-chemokine (alpha chemokine); XC; C-chemokine (gamma chemokine); TNF; tumor necrosis factor; IFN; interferon; LIGHT; homologous to ly
Keywords: FDA; US Food and Drug Administration; BCG; Calmette and Guerin; DC; dendritic cell; APCs; antigen-presenting cells; TSAs; tumor specific antigens; TRA; tumor rejection antigen; gp96; glycoprotein of 96â¯kDa; CTLs; cytotoxic T cells; SEREX; serological an
Keywords: biomarker; cancer outcome; cutaneous adverse event; cutaneous toxicity; oncodermatology; prognostic marker; survival; HFS; hand foot syndrome; HFSR; hand-foot skin reaction; HR; hazard ratio; irAE; immune-related adverse effect; NSCLC; non-small cell
Keywords: ADAM; a disintegrin and metalloproteinase; APP; amyloid precursor protein; APC; antigen presenting cell; Aβ; β-amyloid; B7-H1; B7-homolog 1; CARD; caspase activation and recruitment domain; CCR; C-C chemokine receptor; CIM; C-protein induced myositis; C
Keywords: Small molecules; biologics; adverse effects mouth; BP; Bisphosphonates; EGFR; Epidermal growth factor receptor; FDA; Food and Drug Administration; HER2; Human epidermal growth factor receptor 2; HNSCC; Head and neck squamous cell carcinoma; mAbs; Monoclon
Keywords: 5-fluorouracil; imiquimod; ingenol mebutate; acitretin; American Joint Commission on Cancer; Brigham and Women's Hospital staging system; capecitabine; CDKN2A; cetuximab; chemotherapy; classification; cSCC; CT; cutaneous squamous cell carcinoma; familial
Keywords: HPV; human papilloma virus; CC; cervical cancer; EC; endometrial cancer; CIN; cervical intraepithelial neoplasia; VIN; vulvar intraepithelial neoplasia; VaIN; vaginal intraepithelial neoplasia; CTLA-4; cytotoxic T-lymphocyte-associated antigen 4; PD-1; pr
Keywords: ADA; anti-drug antibodies; AMPK; 5â² adenosine monophosphate-activated protein kinase; aHUS; atypical hemolytic uremic syndrome; AMD; age-related macular degeneration; APC; antigen presenting cells; AT; anaphylatoxin; BTK; Bruton's tyrosine kinase; C1q
Keywords: urinary bladder neoplasms; carcinoma; programmed cell death 1 receptor; immunotherapy; APC; antigen-presenting cell; BCG; bacillus Calmette-Guérin; CD; cluster of differentiation; CR; complete response; CTLA-4; cytotoxic T-lymphocyte-associated antigen-4
Keywords: 5-FU; 5-fluorouracil; AF; atrial fibrillation; ALK; anaplastic lymphoma kinase; APD; action potential duration; APL; acute promyelocytic leukemia; BCR-ABL; breakpoint cluster region-Abelson; BTK; Bruton tyrosine kinase; CD20; cluster of differentiation 20
Keywords: RT; radiation therapy; IFN-γ; interferon-γ; TLR; toll-like receptor; STAT; signal transducer and activator of transcription; NF-κB; nuclear factor-κB; CXCLs; C-X-C motif ligands; CCLs; C-C motif ligands; iNOS; inducible nitric oxide synthase; IL; inte
Keywords: PD-1; PD-L1; Immunotherapy; Checkpoint inhibitors; Biomarkers; Non-small cell lung cancer; Tumor mutational burden; Microbiome;
Keywords: APC; Antigen presenting cells; CIMP; CpG island methylator phenotype; CIN; chromosomal instability; CRC; colorectal cancer; CTLA-4; cytotoxic T lymphocyte-associated protein 4; DAMPs; danger-associated molecular patterns; FDA; US Food and Drug Administr
Keywords: ARID; Age Related Immune Differences; CD40L; CD40 ligand; CTLA-4; cytotoxic T lymphocyte antigen-4; IL; interleukin; Lag3; lymphocyte activation gene 3; MDSC; myeloid derived suppressor cell; MHC; major histocompatibility complex; mTOR; mammalian target o
Keywords: 5-FU; 5-fluoro-uracil; AAV; adeno-associated virus; ADAM; ADAM metallopeptidase domain; ADCC; antibody-dependent cell-mediated cytotoxicity; CCL; chemokine (C-C motif) ligand; CD; cluster of differentiation; CTLA-4; cytotoxic T-lymphocyte-associated ant
Keywords: 5FU; 5-fluorouracil; 95%CI; 95% confidence interval; AA; amino acid; AFP; alpha fetoprotein; AML; actue myeloid leukemia; Ang2; angiopoietin 2; ATP; adenosine triphosphate; BCLC; Barcelona-Clinic Liver Cancer classification; BSC; best supportive care; CAP
Keywords: Urinary cell mRNA profiling; Polymerase chain reaction; Rejection; Tolerance; Kidney transplantation; mRNA; messenger RNA; RT-QPCR; real-time quantitative PCR; ACR; acute cellular rejection; ROC; receiver-operating-characteristic; PI-9; proteinase inhibit
Keywords: ICI; immune checkpoint inhibition; irAE; immune related adverse event; TME; tumor microenvironment; Melanoma; Biomarker; Checkpoint inhibitor; PD-1; CTLA-4;
Keywords: VEGF; vascular endothelial growth factor; TNF-α; tumor-necrosis-factor a; PDGFB; platelet-derived growth factor B; PIGF; placental growth factor; Sema3A; Semaphorin3A; TAM; Tumor-associated macrophages; TEM; Tie2-expressing macrophages; TAN; Tumor-associ
Keywords: BATF; basic leucine zipper transcription factor; BM; bone marrow; Bregs; regulatory B cells; BTLA; B and T lymphocyte attenuator; CFSE; carboxyfluorescein succinimidyl ester; CML; cell mediated lympholysis; CNI; calcineurin inhibitor; CPM; counts per minu
Keywords: ARID; Age Related Immune Dysfunction; BCG; Bacille Calmette-Guérin; CAR; chimeric antigen receptor; CDMRP; Congressionally Directed Medical Research Program; CD40L; CD40 ligand; CpG; poly-(cysteine 5â² to guanine); CRISPR; clustered regularly interspace
Keywords: DC; dendritic cell; tolDCs; tolerogenic dendritic cells; PD-1; programmed cell death 1; PD-L1/PD-L2; programmed cell death ligand 1/2; 17XNL; nonlethal 17X strains; BCG; Mycobacterium bovis Bacillus Calmette Guérin; BMDCs; bone marrow-derived dendritic c
Keywords: mast cells; degranulation; Mas-related G protein-coupled receptor X2; IL-33; adhesion G protein-coupled receptor E2; tryptase; allergy; mastocytosis; ADGRE2; Adhesion G protein-coupled receptor E2; CPA3; Carboxypeptidase 3; CTMC; Connective tissue m
Keywords: NSCLC; non-small cell lung cancer; irAE; immune-related adverse events; IIP; idiopathic interstitial pneumonia; UIP; usual interstitial pneumonia; PD-1; programmed cell death 1; ILD; interstitial lung disease; AE-IIP; acute exacerbation of idiopathic inte
Keywords: Acute pneumonitis; Afatinib; Anti PD-1 antibody; Immune checkpoint inhibitor; EGFR-TKI; epidermal growth factor receptor-tyrosine kinase inhibitor; PD-1; programmed cell death-1; PD-L1; programmed cell death ligand-1; NSCLC; non-small cell lung cancer; BA
Keywords: Tumor immunology; Immunotherapy; T cells; CTLA4; PD-1;
Keywords: EMG; electromyographic examination; IV; intravenous; MRI; magnetic resonance imaging; NCS; nerve conduction study; PD-1; programmed cell death 1; PD-L1; programmed cell death ligand 1; PET; positron emission tomography;
Keywords: CTLA-4; cytotoxic T-lymphocyte-associated protein 4; ICI; immune checkpoint inhibitor; irAE; immune-related adverse event; mRSS; modified Rodnan skin score; PD-1; programmed cell death 1; PD-L1; programmed cell death ligand 1; RNAP3; RNA polymerase III;
Keywords: HLA-G; human leukocyte antigen G; HLA-E; human leukocyte antigen E; PD-L1; programmed cell death 1 ligand 1; IL-10; interleukin-10; TGF-β; transforming growth factor beta; sHLA-G; soluble HLA-G; OL; oral leukoplakia; GB; granzyme B; OPL; oral precancerou
Keywords: bsAb; bispecific antibody; CAR; chimeric antigen receptor; CDN; cyclic dinucleotides; CTL; cytotoxic T lymphocyte; CTLA-4; cytotoxic T-lymphocyte-associated protein 4; GM-CSF; granulocyte-monocyte colony stimulating factor; IR; irradiation; PD-1; Programm
Keywords: Mesothelioma; Immune-checkpoint; Immunotherapy; CTLA-4; PD-1; PD-L1;
Keywords: Cost-effectiveness; Immunotherapy; PD-1; Head and neck cancer; Markov model;
Keywords: Nivolumab; Non-small cell lung cancer; Neutrophil-to-lymphocyte ratio; PD-1; Immunotherapy;
Keywords: Renal cell carcinoma; Tyrosine kinase inhibitor; PD-1; PD-L1; PD-L2;
Keywords: Testicular cancer; Germ cell cancer; PD-1; PD-L1; Checkpoint inhibition; Platinum refractory disease; Immunotherapy;
Keywords: CT; computed tomography; C/T; consolidation/tumor; EGFR; epidermal growth factor receptor; GGO; ground-glass opacity; NSCLC; non-small cell lung cancer; PD-1; programmed death 1; PD-L1; programmed death ligand 1; SUVmax; maximum standardized uptake value;